Management of symptomatic ascites in recurrent ovarian cancer patients using an intra-abdominal semi-permanent catheter
- PMID: 12171424
- DOI: 10.1177/104990910201900108
Management of symptomatic ascites in recurrent ovarian cancer patients using an intra-abdominal semi-permanent catheter
Abstract
Ascites is commonly present in women with advanced-stage ovarian cancer. No standardized protocol exists for the treatment of the patient with recurrent ovarian cancer and rapidly reaccumulating malignant ascites. Palliation of symptoms is most commonly achieved through repeated paracentesis, a procedure that potentially results in injury to intra-abdominal organs, infection, and patient discomfort. Our goal was to improve patient comfort by alleviating symptoms and reducing the need for paracentesis. The Pleurx' catheter offers a number of potential advantages over traditional treatment modalities. Clearly, larger study numbers are required to quantify the morbidity associated with the Pleurx catheter.
Comment in
-
Malignant ascites.Am J Hosp Palliat Care. 2002 Jan-Feb;19(1):7-8. doi: 10.1177/104990910201900101. Am J Hosp Palliat Care. 2002. PMID: 12171427 No abstract available.
Similar articles
-
Long-term semi-permanent catheter use for the palliation of malignant ascites.Gynecol Oncol. 2006 May;101(2):360-2. doi: 10.1016/j.ygyno.2005.12.043. Epub 2006 Feb 24. Gynecol Oncol. 2006. PMID: 16499957
-
Intraoperative placement of a self-retaining Foley catheter for continuous drainage of malignant ascites.Eur J Gynaecol Oncol. 2002;23(1):68-9. Eur J Gynaecol Oncol. 2002. PMID: 11876397
-
Peritoneal catheter site metastasis in a patient with advanced ovarian cancer.Am J Hosp Palliat Care. 2012 May;29(3):241-2. doi: 10.1177/1049909111409390. Epub 2011 May 23. Am J Hosp Palliat Care. 2012. PMID: 21606122
-
PleurX peritoneal catheter drainage system for vacuum-assisted drainage of treatment-resistant, recurrent malignant ascites: a NICE Medical Technology Guidance.Appl Health Econ Health Policy. 2012 Sep 1;10(5):299-308. doi: 10.1007/BF03261864. Appl Health Econ Health Policy. 2012. PMID: 22779402 Review.
-
[Pathogenesis and management of refractory malignant ascites].Bull Cancer. 2011 Jun;98(6):679-87. doi: 10.1684/bdc.2011.1373. Bull Cancer. 2011. PMID: 21636346 Review. French.
Cited by
-
Surgery in platinum-resistant recurrent epithelial ovarian carcinoma.World J Clin Cases. 2022 Apr 26;10(12):3739-3753. doi: 10.12998/wjcc.v10.i12.3739. World J Clin Cases. 2022. PMID: 35647161 Free PMC article.
-
PleurX drain use in the management of malignant ascites: safety, complications, long-term patency and factors predictive of success.Br J Radiol. 2012 May;85(1013):623-8. doi: 10.1259/bjr/24538524. Epub 2011 Mar 22. Br J Radiol. 2012. PMID: 21427184 Free PMC article.
-
Multiline treatment combining apatinib with toptecan for platinum-resistant recurrent ovarian cancer patients: a report of three cases.Onco Targets Ther. 2018 Apr 6;11:1989-1995. doi: 10.2147/OTT.S158141. eCollection 2018. Onco Targets Ther. 2018. PMID: 29670374 Free PMC article.
-
The management of malignant ascites and impact on quality of life outcomes in women with ovarian cancer.Expert Rev Qual Life Cancer Care. 2016;1(3):231-238. doi: 10.1080/23809000.2016.1185369. Epub 2016 May 27. Expert Rev Qual Life Cancer Care. 2016. PMID: 30906877 Free PMC article.
-
Safety and efficacy of the PleurX catheter for the treatment of malignant ascites.J Palliat Med. 2014 Aug;17(8):906-12. doi: 10.1089/jpm.2013.0427. Epub 2014 Jun 2. J Palliat Med. 2014. PMID: 24885753 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical